BMSSC
NBIX icon

B. Metzler seel. Sohn & Co’s Neurocrine Biosciences NBIX Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$785K Buy
5,962
+1,225
+26% +$163K 0.01% 577
2025
Q4 		$672K Sell
4,737
-622
-12% -$90.1K 0.01% 607
2025
Q3 		$752K Hold
5,359
– – 0.01% 592
2025
Q2 		$674K Buy
5,359
+410
+8% +$47K 0.01% 609
2025
Q1 		$547K Sell
4,949
-95
-2% -$12K 0.01% 627
2024
Q4 		$689K Buy
5,044
+245
+5% +$30.3K 0.01% 606
2024
Q3 		$553K Buy
4,799
+2,280
+91% +$313K 0.01% 631
2024
Q2 		$347K Buy
2,519
+121
+5% +$16.6K ﹤0.01% 676
2024
Q1 		$331K Buy
2,398
+445
+23% +$60.8K ﹤0.01% 674
2023
Q4 		$257K Sell
1,953
-2,370
-55% -$273K ﹤0.01% 706
2023
Q3 		$486K Buy
+4,323
New +$455K 0.01% 583
2023
Q1 		– Sell
-1,953
Closed -$233K – 740
2022
Q4 		$233K Buy
+1,953
New +$229K ﹤0.01% 674
2021
Q3 		– Sell
-4,393
Closed -$428K – 713
2021
Q2 		$428K Buy
4,393
+1,287
+41% +$123K 0.01% 577
2021
Q1 		$302K Buy
3,106
+691
+29% +$72.5K 0.01% 617
2020
Q4 		$231K Buy
+2,415
New +$233K ﹤0.01% 633

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

B. Metzler seel. Sohn & Co's NBIX Position: Q1 2026 in Review

B. Metzler seel. Sohn & Co increased its Neurocrine Biosciences (NBIX) stake by 26% in Q1 2026, buying an estimated $163K and bringing the position to 5,962 shares worth $785K. The position accounts for 0.01% of the portfolio, ranked #577.

B. Metzler seel. Sohn & Co first reported a position in NBIX in Q4 2020 and has held it in 15 quarters since. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • B. Metzler seel. Sohn & Co held 5,962 shares of Neurocrine Biosciences worth $785K as of Q1 2026.
  • B. Metzler seel. Sohn & Co bought 1,225 Neurocrine Biosciences shares in Q1 2026, an estimated $163K.
  • Neurocrine Biosciences made up 0.01% of B. Metzler seel. Sohn & Co's portfolio in Q1 2026, its #577 holding.
  • B. Metzler seel. Sohn & Co first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 15 quarters since.
  • 696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q1 2026, filed 8 May 2026.